



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Benralizumab

Chemical Properties

CAS No. : 1044511-01-4

Formula:

Molecular Weight:

Appearance: no data available

Storage: store at low temperature
store at -80°C

Benralizumab

Biological Description

Description	Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5R α). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.
Targets(IC50)	Apoptosis,IL Receptor,Interleukin
In vitro	The dissociation constants of the extracellular domain of recombinant human and cynomolgus IL-11R α by Benralizumab (MEDI-563) were 42 pM and 5 pM, respectively [2]. When inhibiting IL-5-induced proliferation of CTLL-48 cells transfected with recombinant human IL-2R $\alpha\beta$ (5 pM-1 nM, 100 hours), the IC50 of benalizumab was 0.3 nM [2]. Benalizumab specifically binds to constructs containing human IL-5R α D1 and plays a role in mediating ADCC (antibody-dependent cell-mediated cytotoxicity) of human eosinophils and basophils, with EC50 values of 0.9 pM and 0.5 pM, respectively. In addition, it also promotes eosinophil apoptosis [2].
In vivo	Benalizumab (MEDI-563) (0-30 mg / kg ; intravenous injection ; once every 3 weeks for 12 weeks) can reduce peripheral blood and bone marrow eosinophils [2].

Reference

Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5(3). pii: 00009-2019.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481